Skip to main content
AONC logo

American Oncology Network, Inc. (AONC) Stock Price & Analysis

American Oncology Network, Inc. (AONC) — price $11.50 (0.00%), as of the Nov 18, 2026 trading session; market cap $336M.

Educational signal · not a buy or sell recommendation · How to read this

$11.50 $0.00 (0.00%) Market Cap $336M

American Oncology Network, Inc. · AONC

American Oncology Network, Inc. provides comprehensive oncology services across the United States, encompassing laboratory, pathology, specialty pharmacy, and care management support.

Price as of Nov 18, 2026

Key Statistics

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • AUNA · Auna S.A. · 59 /100
  • PIII · P3 Health Partners Inc. · 31 /100
  • CYH · Community Health Systems, Inc. · 52 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$11.50
Change on the day0.00%
52-week range$0.001 – $25.00
Market capitalisation$336M—
Shares traded on the day1.2K

Price & events

Other perspectives

Council score for American Oncology Network (AONC): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Strong
Debt/Equity Negative
ROE Negative
Gross Margin Negative

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is American Oncology Network (AONC), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. American Oncology Network, Inc. (AONC) is the company analyzed here. It employs 1,914 people and is led by Todd Schonherz. In Q4 FY2024 it reported revenue of $491M and net income of $1M. The market values it at $336M.

2 · Latest results

What do the latest results show for American Oncology Network (AONC)?

Short answer · as of

The most recent reported quarter, Q4 FY2024, carried revenue of $491M.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q4 FY2024$491M$1M-$0.0025 (diluted)
Q3 FY2024$470M-$1M-$0.19 (diluted)
Q2 FY2024$434M$4M$0.04 (diluted)
Q1 FY2024$364M-$8M-$1.22 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for American Oncology Network (AONC)?

Short answer · as of

The distress and quality screens read Altman Z 4.67 · Piotroski F 3. Trailing ratios: ROE 5.6% · ROA -0.8% · current ratio 1.53 · earnings yield -1.4% · free-cash-flow yield -4.2%.

The records behind this page

Insider activity

Form 4 records via FMP · Most recent available transactions

Transactions
12
Identified insiders
6
Purchases
4
Sales
0
Other transactions
8

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held AONC in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported AONC in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about American Oncology Network (AONC)?

Read these with our analysis →

American Oncology Network Stock: Key Questions Answered

These answers are editorial: 1 of these 8 answers is drawn from the AONC research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is AONC a good stock to buy?

Stock Expert AI does not rate AONC buy, sell or hold. American Oncology Network, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the AONC stock price today?

The last price recorded for American Oncology Network, Inc. (AONC), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

How does AONC generate revenue?

American Oncology Network, Inc. generates revenue primarily through its diverse range of oncology services. A significant portion of its income stems from fees for diagnostic services provided by its in-house laboratories and pathology departments, which include charges for routine and specialized testing, as well as professional interpretations.

What are the key factors to evaluate for AONC?

Evaluate AONC on fundamentals, analyst consensus, and risk factors. Not financial advice.

How frequently does AONC data refresh on this page?

AONC's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven AONC's recent stock price performance?

American Oncology Network, Inc. (AONC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Integrated model offering comprehensive oncology services, including lab, pathology, specialty pharmacy, and care management. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider AONC overvalued or undervalued right now?

American Oncology Network, Inc. (AONC) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research AONC before investing?

Before investing in American Oncology Network, Inc. (AONC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 14 figures on this page — 8 from Financial Modeling Prep (FMP) and 6 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.